Lung Cancer

Scott Santarella, president, CEO, Bonnie J. Addario Lung Cancer Foundation, discusses some exciting updates in the field of lung cancer.

Fadlo R. Khuri, MD, FACP, professor, chair, hematology/medical oncology, Emory University School of Medicine, deputy director, Winship Cancer Institute, discusses survivorship in lung cancer.

Data on electronic cigarette, or e-cigarettes, suggests that sales are up and it's predicted that e-cigarette sales will exceed cigarette sales in the next decade.

The results of two phase III trials reported at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer have found that enobosarm, a first-in-class, nonsteroidal, oral selective androgen receptor modulator (SARM), led to an increase in lean body mass (LBM) compared with a decline in LBM observed with placebo for patients with non-small cell lung cancer (NSCLC).

Back in 2005, the Surgeon General issued a health advisory about radon, the second leading cause of lung cancer in the United States and called it a completely preventable health threat.

Rebecca Lehto, PhD, RN, OCN, Assistant Professor, College of Nursing, Michigan State University, discusses symptom burden in lung cancer.

Leading experts in the rapidly evolving field of lung cancer treatment assembled for the 1st Annual Miami Lung Cancer Conferenceâ„¢ in Miami Beach, Florida, on March 8, to offer their perspectives on the latest research and provide clinical insights for practitioners dealing with challenging cases.

The FDA has granted an accelerated approval to the next-generation ALK inhibitor ceritinib as a treatment for patients with ALK-positive metastatic non-small cell lung cancer following progression on crizotinib.

I have been living with stage IV lung cancer for three years, not because I have the disease, but because my husband does.

The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.

Nina Grenon, RN, APRN, BC, nurse practitioner, Dana-Farber Cancer Institute, discusses the results of a study that looked at the effect of palliative care in patients with lung cancer.

Differences in lung cancer incidence between men and women narrow with decreasing age.

More and more, as the use of maintenance therapy increases, oncology nurses are tasked with monitoring how the strategy is working for specific patients.

Using different selection criteria for screening is superior to currently recommended criteria.

Donna Berry, from the Dana-Farber Cancer Institute, Explains a Nurse-Led Education Program That Enhanced Oral Therapy Compliance.

The National Comprehensive Cancer Network releases newest update.

CAP is a nonprofit providing information, resource referrals for personal support, and public advocacy for people at risk for or living with lung cancer or hepatitis C.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Will graphic images and stronger warnings decrease cigarette smoking?

Negative attitudes toward smokers extend to patients with lung cancer, regardless of whether or not they have ever actually smoked

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.